These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 14728080

  • 1. Reduction of serum LDL-C levels: a relationship to clinical benefits.
    LaRosa JC.
    Am J Cardiovasc Drugs; 2003; 3(4):271-81. PubMed ID: 14728080
    [Abstract] [Full Text] [Related]

  • 2. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 4. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W, Wieland H.
    Herz; 2000 Mar; 25(2):117-25. PubMed ID: 10829251
    [Abstract] [Full Text] [Related]

  • 5. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS, Goa KL.
    Drugs; 2001 Mar; 61(12):1835-81. PubMed ID: 11693468
    [Abstract] [Full Text] [Related]

  • 6. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting.
    Gotto AM, Grundy SM.
    Circulation; 1999 Mar 02; 99(8):E1-7. PubMed ID: 10051310
    [Abstract] [Full Text] [Related]

  • 7. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR.
    Am J Cardiovasc Drugs; 2010 Mar 02; 10 Suppl 1():10-7. PubMed ID: 21391729
    [Abstract] [Full Text] [Related]

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 02; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 9. Aggressive lipid management for cardiovascular prevention: evidence from clinical trials.
    Friday KE.
    Exp Biol Med (Maywood); 2003 Jul 02; 228(7):769-78. PubMed ID: 12876295
    [Abstract] [Full Text] [Related]

  • 10. Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
    Jones PH.
    Drugs; 2000 May 02; 59(5):1127-35. PubMed ID: 10852644
    [Abstract] [Full Text] [Related]

  • 11. Cholesterol and coronary events. The current thinking.
    Jones PH.
    Postgrad Med; 2003 Apr 02; 113(4 Suppl):5-14. PubMed ID: 19667618
    [Abstract] [Full Text] [Related]

  • 12. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 02; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 13. Low-density lipoprotein cholesterol reduction: the end is more important than the means.
    LaRosa JC.
    Am J Cardiol; 2007 Jul 15; 100(2):240-2. PubMed ID: 17631077
    [Abstract] [Full Text] [Related]

  • 14. [Statins in primary prevention of coronary heart disease].
    Paulweber B.
    Wien Med Wochenschr; 1999 Jul 15; 149(5-6):129-38. PubMed ID: 10408004
    [Abstract] [Full Text] [Related]

  • 15. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR, Tobert JA.
    Drug Saf; 1996 Jan 15; 14(1):11-24. PubMed ID: 8713485
    [Abstract] [Full Text] [Related]

  • 16. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Daskalopoulou SS, Kakafika AI, Pehlivanidis AN, Bouloukos VI, Langer A, GREACE Study Collaborative Group.
    Curr Med Res Opin; 2004 Sep 15; 20(9):1385-92. PubMed ID: 15383187
    [Abstract] [Full Text] [Related]

  • 17. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW.
    Am J Med; 1998 Jul 06; 105(1A):63S-68S. PubMed ID: 9707270
    [Abstract] [Full Text] [Related]

  • 18. Low-density lipoprotein cholesterol: how low can we go?
    Sherbet DP, Garg P, Brilakis ES, Banerjee S.
    Am J Cardiovasc Drugs; 2013 Aug 06; 13(4):225-32. PubMed ID: 23609530
    [Abstract] [Full Text] [Related]

  • 19. Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials.
    Hackam DG.
    Am J Cardiovasc Drugs; 2006 Aug 06; 6(6):367-71. PubMed ID: 17192126
    [Abstract] [Full Text] [Related]

  • 20. New evidence supporting aggressive lipid lowering.
    Stein EA.
    Postgrad Med; 2003 Apr 06; 113(4 Suppl):31-40. PubMed ID: 19667621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.